Hyman Charles D Buys 5,055 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Hyman Charles D lifted its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 20.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 30,128 shares of the medical equipment provider’s stock after purchasing an additional 5,055 shares during the quarter. Hyman Charles D’s holdings in Intuitive Surgical were worth $10,164,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Provence Wealth Management Group bought a new position in shares of Intuitive Surgical during the 4th quarter valued at approximately $276,000. Portside Wealth Group LLC lifted its position in Intuitive Surgical by 8.2% during the fourth quarter. Portside Wealth Group LLC now owns 816 shares of the medical equipment provider’s stock valued at $275,000 after purchasing an additional 62 shares during the last quarter. Sequoia Financial Advisors LLC grew its stake in shares of Intuitive Surgical by 58.0% in the 4th quarter. Sequoia Financial Advisors LLC now owns 8,315 shares of the medical equipment provider’s stock worth $2,805,000 after buying an additional 3,054 shares in the last quarter. Kades & Cheifetz LLC bought a new stake in shares of Intuitive Surgical in the 4th quarter worth about $230,000. Finally, Blair William & Co. IL lifted its holdings in shares of Intuitive Surgical by 3.1% in the 3rd quarter. Blair William & Co. IL now owns 377,371 shares of the medical equipment provider’s stock valued at $110,302,000 after acquiring an additional 11,400 shares during the last quarter. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Intuitive Surgical Price Performance

Intuitive Surgical stock traded down $8.28 during trading hours on Wednesday, reaching $380.37. The stock had a trading volume of 1,107,969 shares, compared to its average volume of 1,601,620. Intuitive Surgical, Inc. has a 52 week low of $254.85 and a 52 week high of $403.76. The company has a market cap of $134.92 billion, a price-to-earnings ratio of 68.66, a PEG ratio of 4.93 and a beta of 1.39. The business’s 50 day moving average price is $385.34 and its 200-day moving average price is $351.97.

Intuitive Surgical (NASDAQ:ISRG) last posted its earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 EPS for the quarter, beating analysts’ consensus estimates of $1.40 by $0.10. The company had revenue of $1.89 billion during the quarter, compared to analysts’ expectations of $1.87 billion. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. Intuitive Surgical’s revenue for the quarter was up 11.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.00 earnings per share. On average, sell-side analysts forecast that Intuitive Surgical, Inc. will post 4.8 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. Piper Sandler boosted their target price on Intuitive Surgical from $425.00 to $435.00 and gave the company an “overweight” rating in a research report on Friday, April 19th. StockNews.com downgraded shares of Intuitive Surgical from a “buy” rating to a “hold” rating in a report on Thursday, February 29th. Mizuho boosted their target price on Intuitive Surgical from $350.00 to $390.00 and gave the company a “neutral” rating in a research report on Thursday, January 25th. Stifel Nicolaus upped their target price on Intuitive Surgical from $420.00 to $430.00 and gave the company a “buy” rating in a research note on Monday, April 8th. Finally, Royal Bank of Canada boosted their price objective on Intuitive Surgical from $400.00 to $432.00 and gave the company an “outperform” rating in a report on Wednesday, January 24th. Five analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $396.17.

Insider Buying and Selling at Intuitive Surgical

In other Intuitive Surgical news, EVP Robert Desantis sold 20,296 shares of the business’s stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $393.80, for a total transaction of $7,992,564.80. Following the sale, the executive vice president now owns 5,507 shares of the company’s stock, valued at approximately $2,168,656.60. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Intuitive Surgical news, EVP Robert Desantis sold 20,296 shares of Intuitive Surgical stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $393.80, for a total transaction of $7,992,564.80. Following the completion of the sale, the executive vice president now owns 5,507 shares of the company’s stock, valued at approximately $2,168,656.60. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Mark Brosius sold 196 shares of the stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $400.00, for a total transaction of $78,400.00. Following the completion of the transaction, the senior vice president now owns 1,842 shares in the company, valued at approximately $736,800. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 147,927 shares of company stock worth $57,064,459. 0.80% of the stock is owned by insiders.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.